9 Meters Biopharma EBIT

9 Meters Biopharma's ebit stands at $-43M as of March 2023. That compares with $-38M in the prior-year period — down 15.5% year over year. That is below the Technology sector average of $67T. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

9 Meters Biopharma reported $-43M in EBIT versus $-38M a year earlier — a 15.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

9 Meters Biopharma sits lower the Technology benchmark ($67T) with a EBIT of $-43M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-38M in the prior-year period — down 15.5% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how 9 Meters Biopharma's EBIT evolved across reporting periods, while the comparison chart places NMTRQ next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.